JP2021512123A5 - - Google Patents
Info
- Publication number
- JP2021512123A5 JP2021512123A5 JP2020541958A JP2020541958A JP2021512123A5 JP 2021512123 A5 JP2021512123 A5 JP 2021512123A5 JP 2020541958 A JP2020541958 A JP 2020541958A JP 2020541958 A JP2020541958 A JP 2020541958A JP 2021512123 A5 JP2021512123 A5 JP 2021512123A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- therapeutic composition
- composition according
- nucleic acid
- arm region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862625623P | 2018-02-02 | 2018-02-02 | |
| US62/625,623 | 2018-02-02 | ||
| PCT/US2019/016413 WO2019152884A1 (en) | 2018-02-02 | 2019-02-01 | Compositions and methods for inducing tripartite motif-containing protein 16 (trim16) signaling |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021512123A JP2021512123A (ja) | 2021-05-13 |
| JP2021512123A5 true JP2021512123A5 (cg-RX-API-DMAC7.html) | 2022-02-03 |
| JP7409612B2 JP7409612B2 (ja) | 2024-01-09 |
Family
ID=67479930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541958A Active JP7409612B2 (ja) | 2018-02-02 | 2019-02-01 | トリパタイトモチーフ含有蛋白質16(trim16)シグナル伝達を誘導するための組成物及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210046168A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3746088B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7409612B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102828978B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111836623A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019215191B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020015821A2 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2020128838A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019152884A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
| WO2021194672A1 (en) | 2020-03-23 | 2021-09-30 | Hdt Bio Corp. | Compositions and methods for delivery of rna |
| JP2022550454A (ja) * | 2019-10-02 | 2022-12-01 | ユニバーシティ オブ ワシントン | B型肝炎ウイルス感染の治療のための組成物及び方法 |
| EP4058581A1 (en) * | 2019-11-15 | 2022-09-21 | Infectious Disease Research Institute | Rig-i agonist and adjuvant formulation for tumor treatment |
| EP4112665A4 (en) * | 2020-03-27 | 2024-04-10 | Mitsui Chemicals, Inc. | LIGHT-CURING COMPOSITION, CURED PRODUCT AND DENTAL PRODUCT |
| KR20240043747A (ko) | 2021-07-02 | 2024-04-03 | 예일 유니버시티 | 암을 치료하기 위한 조성물 및 방법 |
| JP2024532621A (ja) | 2021-08-31 | 2024-09-05 | イエール ユニバーシティ | がんを治療するための組成物および方法 |
| AU2022352486A1 (en) | 2021-09-22 | 2024-04-11 | Hdt Bio Corp. | Dried nanoparticle compositions |
| CA3232658A1 (en) | 2021-09-22 | 2023-03-30 | Steven Gregory REED | Rna vaccines against infectious diseases |
| WO2023049636A2 (en) | 2021-09-22 | 2023-03-30 | Hdt Bio Corp. | Cancer therapy compositions and uses thereof |
| JP2024535352A (ja) | 2021-09-22 | 2024-09-30 | エイチディーティー バイオ コーポレーション | Sars-cov-2 rnaワクチン組成物および使用方法 |
| AU2023228912A1 (en) | 2022-03-03 | 2024-09-19 | Yale University | Humanized 3e10 antibodies, variants, and antigen binding fragments thereof |
| WO2026039779A1 (en) | 2024-08-15 | 2026-02-19 | Yale University | Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003218181A1 (en) | 2002-03-15 | 2003-09-29 | Multicell Immunotherapeutics, Inc. | Immunostimulatory double stranded RNA and methods of inducing, enhancing or modulating the immune response |
| JP2010500011A (ja) | 2006-08-08 | 2010-01-07 | ガンサー ハートマン | 5’リン酸オリゴヌクレオチドの構造および使用 |
| BRPI1100857A2 (pt) * | 2011-03-18 | 2013-05-21 | Eduardo Nowill Alexandre | agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real |
| US9775894B2 (en) * | 2013-07-09 | 2017-10-03 | University Of Washington Through Its Center For Commercialization | Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling |
| US10624964B2 (en) * | 2015-05-01 | 2020-04-21 | The Trustees Of The University Of Pennsylvania | Methods and compositions for stimulating immune response using potent immunostimulatory RNA motifs |
| CN117244049A (zh) * | 2016-02-16 | 2023-12-19 | 哈佛学院院长等 | 病原体疫苗及其生产和使用方法 |
-
2019
- 2019-02-01 AU AU2019215191A patent/AU2019215191B2/en active Active
- 2019-02-01 KR KR1020207025399A patent/KR102828978B1/ko active Active
- 2019-02-01 US US16/966,851 patent/US20210046168A1/en active Pending
- 2019-02-01 WO PCT/US2019/016413 patent/WO2019152884A1/en not_active Ceased
- 2019-02-01 JP JP2020541958A patent/JP7409612B2/ja active Active
- 2019-02-01 RU RU2020128838A patent/RU2020128838A/ru unknown
- 2019-02-01 BR BR112020015821-6A patent/BR112020015821A2/pt unknown
- 2019-02-01 CN CN201980018082.3A patent/CN111836623A/zh active Pending
- 2019-02-01 EP EP19748292.0A patent/EP3746088B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020128838A (ru) | Композиции и способы для индуцирования передачи сигнала белка, содержащего трехсторонний мотив, 16 (trim16) | |
| JP2548527B2 (ja) | 腫瘍壊死因子の産生を増加する方法 | |
| RU2009117325A (ru) | Слитый белок теломеразной обратной транскриптазы, кодирующие его нуклеотиды и их применение | |
| JP2019193662A5 (cg-RX-API-DMAC7.html) | ||
| Matveeva et al. | Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency | |
| JP2008056679A5 (cg-RX-API-DMAC7.html) | ||
| JP2014506913A5 (cg-RX-API-DMAC7.html) | ||
| TR200700740T2 (tr) | Nogo genlerinin nükleotid ve protein dizileri ve bunlar bazında yöntemler | |
| AR079555A1 (es) | Metodos de tratamiento de la infeccion de virus de hepatitis b (hbv) y virus de hepatitis c (hcv) | |
| CN115176009A (zh) | 用于靶向pd-l1的方法和组合物 | |
| JP2021525549A5 (cg-RX-API-DMAC7.html) | ||
| JP2024513559A5 (cg-RX-API-DMAC7.html) | ||
| JP2023510121A5 (cg-RX-API-DMAC7.html) | ||
| JP2023522630A5 (cg-RX-API-DMAC7.html) | ||
| JP2003530088A5 (cg-RX-API-DMAC7.html) | ||
| JP2013511975A5 (cg-RX-API-DMAC7.html) | ||
| JP2022507373A5 (cg-RX-API-DMAC7.html) | ||
| RU2004122084A (ru) | Пептиды для лечения рака, ассоциированного с папилломавирусом (hpv) человека, и других эпителиальных опухолей | |
| JP2021536239A5 (cg-RX-API-DMAC7.html) | ||
| EP3022297A1 (en) | Genetically stable oncolytic rna virus, method of manufacturing and use thereof | |
| CN104292337A (zh) | 猪融合干扰素 | |
| RU2020100072A (ru) | Иммуногенные композиции, содержащие cea, muc1 и tert | |
| JP2024503703A5 (cg-RX-API-DMAC7.html) | ||
| AU2012281131B2 (en) | Novel zinc finger-like peptide compositions as potent agents in cancer prevention and treatment | |
| FI3335725T3 (fi) | Pds5a-epitooppeja immuuniteetin indusoijina |